Datapoint: GSK’s Latest Oncology Buy Includes Jakafi Competitor

GlaxoSmithKline last week unveiled plans to purchase Sierra Oncology for $1.9 billion. The highlight of the deal is momelotinib, Sierra’s promising JAK inhibitor. In a recent phase 3 clinical trial, momelotinib outperformed Incyte and Novartis’ Jakafi in controlling myelofibrosis, a rare blood cancer, and prevented anemia in patients. Sierra intends to file for FDA approval during the second quarter of 2022. For the treatment of myelofibrosis, virtually all insured lives have covered or better access to Jakafi. 17.5% of lives have preferred access to Jakafi without utilization management restrictions.

SOURCE: MMIT Analytics, as of 4/13/22

0

0

0 Comments

0

0

• Datapoint